Posaconazole for the Treatment of Oropharyngeal Candidiasis, Including Triazole-Resistant Disease, in HIV-positive Patients

Clinical Medicine Insights: Therapeutics - New Zealand
doi 10.4137/cmt.s5434
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Local Immunity in Hematological Patients With Oropharyngeal Candidiasis

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2015English

Miconazole Mucoadhesive Tablet for Oropharyngeal Candidiasis

Expert Review of Anti-Infective Therapy
VirologyInfectious DiseasesMicrobiology
2011English

Multiple Resistant Phenotypes of Candida albicansCoexist During Episodes of Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1999English

Oral Candidiasis in HIV+ Patients Under Treatment With Protease Inhibitors

Brazilian Oral Research
2008English

Mouse Model of Oropharyngeal Candidiasis

Nature Protocols
BiochemistryGeneticsMolecular Biology
2012English

Renal Disease Among HIV Positive Patients in Senegal

Open Journal of Nephrology
2017English

Pulmonary Candidiasis and CD4 Count in HIV Positive Patients Seen in Jos, North Central Nigeria

African Journal of Clinical and Experimental Microbiology
2015English

Triazole Use in the Nursery: Fluconazole, Voriconazole, Posaconazole, and Ravuconazole

Current Drug Metabolism
Clinical BiochemistryPharmacology
2013English

Oropharyngeal Candidiasis in HIV Infection: Analysis of Impaired Mucosal Immune Response to Candida Albicans in Mice Expressing the HIV-1 Transgene

Pathogens
ImmunologyMolecular BiologyAllergyMicrobiologyMicrobiology Infectious Diseases
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy